uniQure (NASDAQ:QURE) Shares Gap Down – Time to Sell?

uniQure (NASDAQ:QURE)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $14.53, but opened at $14.07. uniQure shares last traded at $13.83, with a volume of 60,923 shares.

Analyst Ratings Changes

A number of analysts have recently weighed in on QURE shares. Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. The Goldman Sachs Group upped their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, Leerink Partners upped their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Stock Performance

The stock’s 50-day moving average is $13.83 and its 200-day moving average is $10.39. The firm has a market capitalization of $759.24 million, a price-to-earnings ratio of -2.83 and a beta of 0.36. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the transaction, the chief executive officer now owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its position in shares of uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after buying an additional 752,889 shares during the period. Walleye Capital LLC acquired a new stake in shares of uniQure during the third quarter worth $444,000. FMR LLC increased its position in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares during the period. Sanders Morris Harris LLC increased its position in shares of uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after buying an additional 34,034 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of uniQure during the third quarter worth $7,360,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.